Top

Published in:

Open Access 01-12-2010 | Review

Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology

Authors: Antonio Sacco, Ghayas C Issa, Yong Zhang, Yang Liu, Patricia Maiso, Irene M Ghobrial, Aldo M Roccaro

Published in: Journal of Hematology & Oncology | Issue 1/2010

Abstract

Waldenstrom's Macroglobulinemia is a low-grade B-cell lymphoma characterized by the presence of lymphoplasmacytic cells in the bone marrow and a monoclonal immunoglobulin M in the circulation. Recent evidences support the hypothesis that epigenetic modifications lead to Waldesntrom cell proliferation and therefore play a crucial role in the pathogenesis of this disease. Indeed, while cytogenetic and gene expression analysis have demonstrated minimal changes; microRNA aberrations and modification in the histone acetylation status of primary Waldenstrom Macroglobulinemia tumor cells have been described. These findings provide a better understanding of the underlying molecular changes that lead to the initiation and progression of this disease.

Available only for authorised users

Waddington CH: Preliminary notes on the development of the wings in normal and mutant strains of drosophila. Proc Natl Acad Sci USA. 1939, 25: 299-307. 10.1073/pnas.25.7.299.PubMedCentralCrossRefPubMed

Mack GS: Epigenetic cancer therapy makes headway. J Natl Cancer Inst. 2006, 98: 1443-1444.CrossRefPubMed

Ghobrial IM, Gertz MA, Fonseca R: Waldenstrm macroglobulinaemia. Lancet Oncol. 2003, 4: 679-685. 10.1016/S1470-2045(03)01246-4.CrossRefPubMed

Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA: Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003, 30: 110-115. 10.1053/sonc.2003.50082.CrossRefPubMed

Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL: Gene expression profiling of Waldenström's macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006, 108: 2755-2763. 10.1182/blood-2006-02-005488.PubMedCentralCrossRefPubMed

Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM: microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010, 116: 1506-1514. 10.1182/blood-2010-01-265686.PubMedCentralCrossRefPubMed

Lee RC, Feinbaum RL, Ambros V: The C-Elegans heterochronic gene Lin-4 encodes small RNAs with antisense complementarity to Lin-14. Cell. 1993, 75: 843-854. 10.1016/0092-8674(93)90529-Y.CrossRefPubMed

Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES, Kellis M: Systematic discovery of regulatory motifs in human promoters and 3'UTRs by comparison of several mammals. Nature. 2005, 434: 338-345. 10.1038/nature03441.PubMedCentralCrossRefPubMed

He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004, 5: 522-531. 10.1038/nrg1379.CrossRefPubMed

10.

Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behaviour. J Clin Oncol. 2006, 24: 4677-4684. 10.1200/JCO.2005.05.5194.CrossRefPubMed

11.

Lu J, Getz g, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-838. 10.1038/nature03702.CrossRefPubMed

12.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65: 7065-7070. 10.1158/0008-5472.CAN-05-1783.CrossRefPubMed

13.

Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM: MicroRNA profiling reveals distinctive signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004, 101: 11755-11760. 10.1073/pnas.0404432101.PubMedCentralCrossRefPubMed

14.

Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM: microRNA expression in the biology, prognosis and therapy of Waldenstrom Macroglobulinemia. Blood. 2009, 113: 4391-4402. 10.1182/blood-2008-09-178228.PubMedCentralCrossRefPubMed

15.

Tam W, Dahlberg JE: miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer. 2006, 45: 211-212. 10.1002/gcc.20282.CrossRefPubMed

16.

Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005, 102: 3627-3632. 10.1073/pnas.0500613102.PubMedCentralCrossRefPubMed

17.

Rai D, Karanti S, Jung I, Dahia PL, Aguiar RC: Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet. 2008, 181: 8-15. 10.1016/j.cancergencyto.2007.10.008.PubMedCentralCrossRefPubMed

18.

Kluvier J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A: BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005, 207: 243-249. 10.1002/path.1825.CrossRef

19.

Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC: The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006, 42: 1564-1573. 10.1016/j.ejca.2005.12.025.CrossRefPubMed

20.

Chan PM, Lim L, Manser E: PAK is regulated by PI3K, PIX, Cdc42 and PP2Calpha and mediates focal adhesion turnover in the hyperosmotic stress-induced P38 pathway. J Biol Chem. 2008, 283: 24949-24961. 10.1074/jbc.M801728200.PubMedCentralCrossRefPubMed

21.

Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM: Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007, 109: 2708-2717.PubMedCentralPubMed

22.

Mack GS: Epigenetic cancer therapy makes headway. J Natl Cancer Inst. 2006, 98: 1443-1444.CrossRefPubMed

23.

Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell. 2007, 128: 669-681. 10.1016/j.cell.2007.01.033.CrossRefPubMed

24.

Liu PY, Chan JY, Lin HC, Wang SL, Liu ST, Ho CL, Chang LC, Huang SM: Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells. Mol Cancer Res. 2008, 6: 1204-1214. 10.1158/1541-7786.MCR-08-0123.CrossRefPubMed

25.

Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5: 769-784. 10.1038/nrd2133.CrossRefPubMed

26.

Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D, Orntoft TF, Aaltonen LA, Schwartz S, Esteller M: A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet. 2006, 38: 566-569. 10.1038/ng1773.CrossRefPubMed

27.

Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci. 2007, 140: 15805-15810. 10.1073/pnas.0707628104.CrossRef

28.

Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K: The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature. 2006, 442: 307-311. 10.1038/nature04837.CrossRefPubMed

29.

Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G: MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene repression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009, 113: 6411-6418. 10.1182/blood-2008-07-170589.PubMedCentralCrossRefPubMed

30.

Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009, 28: 1714-1724. 10.1038/onc.2009.19.CrossRefPubMed

31.

Varambally S, Cao Q, Maini RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008, 322: 1695-1699. 10.1126/science.1165395.PubMedCentralCrossRefPubMed

32.

Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou X, Jones PA: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 2009, 69: 2623-2629. 10.1158/0008-5472.CAN-08-3114.CrossRefPubMed

Title: Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology
Authors: Antonio Sacco
Ghayas C Issa
Yong Zhang
Yang Liu
Patricia Maiso
Irene M Ghobrial
Aldo M Roccaro
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2010
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-3-38

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Ovarian cancer immunotherapy: opportunities, progresses and challenges

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma

Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

Acute dyspnoea and single tracheal localisation of mantle cell lymphoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer